Monoclonal antibody treatment for severe uncontrolled asthma in Spain : analytical map
Casas-Maldonado, Francisco (Hospital Universitario Clinico San Cecilio (Granada, Andalusia))
Alvarez Gutiérrez, Francisco Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Blanco-Aparicio, Marina (Complejo Hospitalario Universitario de A Coruña)
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Cisneros, Carolina (Hospital Universitario de la Princesa (Madrid))
Soto Campos, Gregorio (Hospital Universitario de Jerez (Jerez de la Frontera))
Román Bernal, Berta (Hospital Universitario Doctor José Molina Orosa)
González-Barcala, Francisco-Javier (Universidade de Santiago de Compostela)
Universitat Autònoma de Barcelona. Departament de Medicina

Imprint:	Informa Healthcare, 2021
Abstract:	Background: Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments. Objective: To evaluate the proportion of patients with SUA treated with mABs in Spain, and to analyze some of the factors that could determine these prescription patterns. Methods: An analysis was performed on the data provided from the Hospitals National Health System (NHS) 2018 catalogue where Chest Diseases Department and a Hospital Pharmacy were available. Random sampling was performed to determine the sample size, stratifying proportionally by geographic area and hospital level. Characteristics of the participating sites, as well as the prescribing of mABs were collected, which included geographic area, hospital levels, prescribing medical specialities, types of clinics, and mABs prescribed. Results: Data from 90 hospitals were analyzed (Response rate 64. 3%). Level 4 hospitals, the Canary Islands geographical area, and the presence of a high complexity Asthma Healthcare Unit (ACU) were associated with a higher probability that the SUA was treated with mABs. Conclusion: The map of the prescribing of mABs for SUA in Spain shows a significant variation by geographic area, hospital level, type of clinic, and the accreditation level of the ACUs. At the current time, there appears to be significant under-prescribing of these treatments.
Note:	Altres ajuts: FORO AUTONOMICO DE ASMA-SEPAR (Spanish Respiratory Society)
Rights:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Language:	Castellà
Document:	Article ; recerca ; Versió acceptada per publicar
Subject:	Severe asthma ; Monoclonal antibodies ; Mepolizumab ; Dupilumab ; Omalizumab ; Reslizumab ; Benralizumab
Published in:	Journal of Asthma, Vol. 59, Num.10 (october 2022) , p. 1997-2007, ISSN 1532-4303

DOI: 10.1080/02770903.2021.1978483

21 p, 332.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles